Sarcomas collectively represent over 100 different subtypes of bone and soft tissue tumors of mesenchymal origin. The low response rate to cytotoxic chemotherapies has necessitated the need for development of either histologically driven or pathway-specific targeted therapies. As our understanding of the molecular mechanisms driving certain subtypes is rapidly advancing, the number of targeted therapies is also increasing. Recently identified novel druggable targets include the MDM2 amplifications in well-differentiated and dedifferentiated liposarcomas, the new translocation NAB2:STAT6 of solitary fibrous tumors, the angiopoeitin-TIE2 pathway in angiosarcoma, the suppression of Mcl1 in X:18/synovial sarcomas, the mTOR pathway in malignant peripheral nerve sheath tumors, CDK4 in alveolar rhabdomyosarcoma, cMET regulation in alveolar soft parts sarcoma, the metabolic abnormalities in wild-type/SHD GIST, and the lack of argininosuccinate synthetase 1 expression seen in most sarcomas. It is through a fundamental understanding of sarcoma biology that clinical trials based on molecular targets can be developed.

Original languageEnglish
Pages (from-to)378-385
Number of pages8
JournalCurrent oncology reports
Issue number4
StatePublished - Aug 2013


  • Alveolar rhabdomyosarcoma
  • Angiopoeitin
  • Angiosarcoma
  • Argininosuccinate Synthetase 1
  • Bone sarcoma
  • CKD4
  • Liposarcoma
  • MDM2
  • Malignant peripheral nerve sheath tumors
  • Mcl1
  • NAB2:STAT6
  • SDH ASS1
  • Sarcoma
  • Soft tissue sarcoma
  • Solitary fibrous tumors
  • Succinate dehydrogenase
  • Synovial sarcoma
  • TIE2
  • Wild-type GIST
  • X:18 sarcoma
  • cMET
  • mTOR


Dive into the research topics of 'Novel pathways and molecular targets for the treatment of sarcoma'. Together they form a unique fingerprint.

Cite this